Palvella Therapeutics, Inc. (NasdaqGM: PVLA)
Health Care · Biotechnology · US
$132.89
-4.24% today · +82.1% 1Y
Palvella Therapeutics, Inc. (NasdaqGM: PVLA) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.00B and employs 29 people.
Over the last twelve months the share price has gained 82.1%, trading between 65.93 and 161.38.
Tweenvest scores Palvella Therapeutics, Inc. across four factors: quality 43/100, value 67/100. Its strongest factor is value.
PVLA price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.00B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -4.90
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $161.38
- 52-week low
- $65.93
- Avg volume (3M)
- —
- Shares outstanding
- 14.41M
- Employees
- 29
- Next earnings
- —
About Palvella Therapeutics, Inc.
Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for patients afflicted with severe and uncommon inherited skin conditions. Central to its pipeline is QTORIN 3.9% rapamycin anhydrous gel (referred to as QTORIN rapamycin), which is currently undergoing Phase 3 clinical trials for microcystic lymphatic malformations. Additionally, this drug is in Phase 2 evaluation for treating cutaneous venous malformations. Beyond these specific indications, Palvella is also advancing QTORIN rapamycin for the treatment of other dermatological diseases driven by the mTOR pathway. The company's headquarters are situated in Wayne, Pennsylvania.
- ISIN
- US6979471090
- Listed since
- Jan 2, 2015
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Vericel CorporationNasdaqGM: VCEL | $2.05B | $40.28 | +0.45% |
| Nanjing Vazyme Biotech Co., LtdSHSE: 688105 | $2.05B | CN¥26.60 | -2.35% |
| Wuhan Healthgen Biotechnology Corp.SHSE: 688765 | $2.02B | CN¥37.86 | -4.97% |
| Genus plcLSE: GNS | $2.02B | £22.72 | -0.35% |
| ABL Bio Inc.KOSDAQ: A298380 | $2.00B | ₩48,000.00 | -6.61% |
| ADARx Pharmaceuticals, Inc.NasdaqGS: ADRX | $1.99B | $17.78 | 0.00% |
| OliX Pharmaceuticals, IncKOSDAQ: A226950 | $1.99B | ₩117,300.00 | +0.43% |
| Vir Biotechnology, Inc.NasdaqGS: VIR | $1.98B | $11.36 | -2.91% |
Figures last refreshed Oct 11, 2026.